Unknown NA INTERVENTIONAL NCT00498992

Regenecare® Wound Gel in Treating Rash in Patients Receiving Cetuximab or Other Epidermal Growth Factor Receptor Inhibitor Therapy for Cancer

Regenecare® in the Treatment of Skin Rash Associated With Cetuximab (Erbitux®) or Other EGFR Treated Cancer Patients

Sponsor: Ingalls Memorial Hospital

Conditions Dermatologic Complications Unspecified Adult Solid Tumor, Protocol Specific

Interventions collagen/aloe vera/vitamin E/lidocaine topical hydrogel

Updated 5 times since 2017 Last updated: Sep 19, 2013 Started: Jul 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00498992, this NA trial focuses on Dermatologic Complications and Unspecified Adult Solid Tumor, Protocol Specific and remains ongoing. Sponsored by Ingalls Memorial Hospital, it has been updated 5 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status NA
Jun 2018 — Jan 2021 [monthly]

Unknown Status NA
Jan 2017 — Jun 2018 [monthly]

Unknown Status NA

First recorded

Jul 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ingalls Memorial Hospital

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Harvey, United States